Novo Nordisk Secures Key EU Approval for Higher-Dose Weight-Loss Drug
19.02.2026 - 13:58:07 | boerse-global.de
Novo Nordisk has received crucial regulatory backing from Brussels, providing a positive counterpoint to recent stock market declines and heightened competitive pressures. The European Commission has approved a high-dose formulation of the blockbuster weight-loss medication Wegovy, a strategic move analysts view as essential for the pharmaceutical giant to defend its market leadership against rivals such as Eli Lilly.
This authorization arrives at a pivotal moment for the company. Novo Nordisk’s shares have faced significant pressure, shedding approximately 48 percent of their value over a twelve-month period. This downturn was partly fueled by disappointing 2026 forecasts, which project a currency-adjusted sales decline of up to 13 percent. The EU’s green light for Read more...
Hol dir den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Trading-Empfehlungen – dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr.
Jetzt abonnieren.
